Skip to main content

pitavastatin

Generic: PITAVASTATIN CALCIUM·Brand: LIVALO, Livalo, NIKITA, Nikita, PITAVASTATIN CALCIUM, Zypitamag

pitavastatin: 4 clinical trials tracked.

pitavastatin evidence translation

What we can confirm

4 tracked trials

No verified listed company relationship

What it means

AI will separate confirmed drug evidence from unknown company context.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

What is verified about pitavastatin, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence6 indications · 2 study sponsors
Clinical Trial Registry Records (4)

A Phase 1 Study to Evaluate the Effect of Multiple Doses of ABBV-722 on the Pharmacokinetics of Cocktail Probe Substrates of CYP3A and Select Transporters in Healthy Adult Subjects

NCT07567781Registry updated 2026-08-20·Phase 1·ABBV
Completed

Primary endpoint: Number of Participants with Adverse Events (AEs)

Interventionalopen12 enrolledStarted 2026-04Completion 2026-071 site · United StatesAbbVie

An Open-Label, Fixed-Sequence Study to Evaluate the Effect of Etavopivat on the Single-Dose Pharmacokinetics of Midazolam, Digoxin, Rosuvastatin, Pitavastatin, and Metformin in Healthy Adult Participants

NCT06813924Registry updated 2026-09-29·Phase 1·NVO
Completed

Primary endpoint: Cmax, digoxin, SD: Maximum observed digoxin plasma concentration with and without etavopivat at steady state

Interventionalopen37 enrolledStarted 2025-02Completion 2025-051 site · United StatesNovo Nordisk A/S

A Phase 1 Open-Label, Dose Escalation Study of Pitavastatin in Combination With Venetoclax in Patients With Chronic Lymphocytic Leukemia or Acute Myeloid Leukemia

NCT04512105Registry updated 2025-09-11·Phase 1
Completed

Primary endpoint: Maximum Tolerated Dose for PIT administered with VEN-containing Standard of Care (SOC) regimens

Interventionalopen6 enrolledStarted 2020-12Completion 2025-021 site · United StatesUniversity of California, Irvine

Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE

NCT02344290Registry updated 2025-09-04·Phase 3
Completed

Primary endpoint: Incidence Rate of Major Adverse Cardiovascular Event (MACE)

InterventionalRandomizedquadruple7,769 enrolledStarted 2015-03Completion 2023-0850 sites · United StatesNational Institute of Allergy and Infectious Diseases (NIAID)